Eczema is extremely common in children. Most the time it is easily treated with topical steroids but on occasion it requires systemic therapies. JAMA Pediatrics Editor Dimitri Christakis, MD, MPH, and JAMA Network Open Editor Frederick Rivara, MD, MPH, discuss the results of a clinical trial of a new monoclonal antibody intended to improve eczema in children that was published in the January 2020 issue of JAMA Pediatrics. Related: Are Bacteria Transplants the Future of Eczema Therapy? Effect of an Intervention to Promote Breastfeeding on Asthma, Lung Function, and Atopic Eczema at Age 16 Years: Follow-up of the PROBIT Randomized Trial Persistence of Childhood Eczema Into Adulthood Association Between Eczema and Stature in 9 US Population-Based Studies Healthcare Utilization, Patient Costs, and Access to Care in US Adults With Eczema: A Population-Based Study Management of Atopic Dermatitis Anti-IgE Medication Lessens Pediatric Atopic Dermatitis Severity Atopic Eczema